Antimicrobial Resistance Diagnostics Market Size, Share & Forecast 2026-2032
AMR diagnostics estimates agree to 1.02x at the base year. A test against bioMerieux's disclosed revenue shows why the market grows at only 6%.
$5.3B
$7.6B
6.26%
Global
Executive Summary
This market is the unusual case in which the published estimates agree, and the agreement is more troubling than any disagreement would be. Global Market Insights puts antimicrobial resistance diagnostics at $4.4 billion for 2023; Global Industry Analysts puts it at $4.5 billion for 2024. Two independent houses, one year apart, 1.02x apart. The only material scope gap in the literature is between broad AMR diagnostics and susceptibility testing alone, which is 1.54x at 2030 ($7.3 billion against $4.736 billion). Published growth rates span 5.1% to 8.51%, a 1.67x spread.
So the finding is not that nobody knows how big this market is. The finding is that everybody agrees it is about four and a half billion dollars growing at five or six per cent a year, at a moment when the World Health Organization reports that one in six laboratory-confirmed bacterial infections worldwide was resistant to treatment in 2023, and that resistance rose in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023 at 5 to 15% a year. The diagnostics market addressing that is growing more slowly than the problem.
Two pieces of arithmetic make the structure concrete. bioMérieux, the acknowledged leader in clinical microbiology and susceptibility testing, disclosed microbiology sales of 320.4 million euros in the second quarter of 2025; annualised and converted that is roughly $1.40 billion, about 31.5% of the entire published global market -- and that franchise includes blood culture and organism identification as well as susceptibility, so the ratio is an upper bound and still a third. This is a concentrated instrument-and-reagent installed base, not a growth market, and that is exactly what a 6% rate describes.
The second calculation is harder to read. Dividing the $4.45 billion market by the 104 countries reporting to WHO's GLASS surveillance system in 2023 gives $42.8 million of global diagnostics spend per reporting country per year, in a market where Global Market Insights alone sizes the United States at $3.1 billion by 2032. The regions with one-in-three resistance rates are not the regions buying the diagnostics, and 48% of countries reported no GLASS data at all in 2023.
Key Highlights
Published base-year estimates agree to within 1.02x: $4.4 billion for 2023 and $4.5 billion for 2024 from two independent houses
The only material scope gap is 1.54x at 2030, broad AMR diagnostics at $7.3 billion against susceptibility testing alone at $4.736 billion
bioMérieux's disclosed Q2 2025 microbiology sales annualise to roughly $1.40 billion, about 31.5% of the whole published market
That ratio rules in a concentrated instrument installed base and rules out a large, fragmented market with many billion-dollar participants
WHO found one in six laboratory-confirmed bacterial infections resistant in 2023, with resistance rising 5 to 15% a year in over 40% of monitored combinations
$4.45 billion divided by the 104 GLASS-reporting countries is $42.8 million per country per year, against a United States figure one house puts at $3.1 billion by 2032
48% of countries reported no GLASS data for 2023, and about half of those that did lacked systems to generate reliable data
Market Overview
Market Context
Antimicrobial resistance diagnostics is the business of answering two clinical questions: which organism is causing this infection, and which drugs will still kill it. The second question is antimicrobial susceptibility testing, and it has been performed essentially the same way for decades -- grow the organism, expose it to a panel of agents, read the growth inhibition -- on automated platforms whose economics are those of an instrument placed once and reagents pulled through for a decade afterwards. That structure explains the numbers. The published market is small, around four and a half billion dollars, concentrated, and growing at the rate of reagent pull-through rather than at the rate of the underlying disease. bioMérieux's own disclosures illustrate it precisely: excluding China, the VITEK and BACT/ALERT ranges grew 9% in the second quarter of 2025 on both instruments and reagents, while microbiology sales in China fell by mid-teens and full-year microbiology organic growth came in at 4%. The swing factor was a procurement regime, not a pathogen. The mismatch with the epidemiology is the thing worth understanding. WHO's 2025 surveillance report, published 13 October 2025, found resistance highest in the South-East Asia and Eastern Mediterranean regions, where one in three reported infections was resistant, and in the African Region at one in five. Those are the health systems least able to buy automated susceptibility platforms. WHO also found that about half of the countries reporting to GLASS still lacked the systems to generate reliable data. The diagnostic capacity that surveillance depends on is precisely the capacity this market has not reached, and no forecast in the published literature assumes it will.
Antimicrobial resistance diagnostics is $5.28 billion in 2026 on the published series with the clearest base and endpoint, projected to $7.60 billion by 2032 at a 6.26% CAGR. Published base-year estimates agree unusually closely, 1.02x apart across two independent houses, and the only material scope gap is 1.54x between broad AMR diagnostics and susceptibility testing alone. The analytical point is the agreement rather than the spread: a $4.5 billion market growing at 6% is the market of a concentrated instrument installed base being maintained, not of a global health emergency being addressed, while WHO reports resistance rising 5 to 15% a year.
Market Stage
Mature
Adoption Level
Universal in high-income hospital microbiology; largely absent where resistance is highest
Key Trends
Market Forecast & Data
Base Year (2026)
$5.3B
Forecast (2032)
$7.6B
CAGR (2026-2032)
6.26%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $5.28B |
| 2027 | $5.61B |
| 2028 | $5.96B |
| 2029 | $6.33B |
| 2030 | $6.73B |
| 2031 | $7.15B |
| 2032 | $7.60B |
The curve shown here is modelled at a constant 6.26% rate. Global Market Insights publishes $4.4 billion for 2023 and $7.6 billion for 2032, which reconcile at 6.26% compound over nine years, consistent with the firm's own stated 'over 6.3%'. The 2026 base of $5.28 billion is the published 2023 value advanced three years at that implied rate; the 2032 endpoint is GMI's own published figure, unmodified. The intermediate years are interpolation, not separately sourced observations. This series was chosen because it is the only one with both an explicit base-year value and an explicit endpoint inside the forecast window, because an independent house corroborates its base year to within 1.02x, and because it survives both grounding tests. Readers working to a susceptibility-testing-only definition should anchor lower -- the AST cluster runs $4.736 billion to $5.986 billion at 2030 -- and should expect a similar rate, since published AST rates of 5.1% to 6.8% sit inside the broader range. The top of the published range, 8.51%, is difficult to reconcile with the evidence. For the whole market to compound at 8.51%, the two-thirds of it outside bioMérieux's microbiology franchise would have to grow at roughly 11% while the leader grew at 4% organically, and no public filing evidences a participant of that size doing so. The realistic upside case is not faster growth in the existing installed base. It is a step change in where that base is installed, and nothing in the published forecasts prices one in.
Market Dynamics
- A rising burden that is measured rather than asserted: WHO found resistance increasing in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023, at 5 to 15% a year
- Antimicrobial stewardship programmes that require a susceptibility result to justify de-escalation, making the test a condition of the prescribing policy
- Reagent pull-through on a long-lived automated installed base, which produces durable revenue independent of new placements
- Rapid molecular resistance-gene detection, which commands a materially higher price per test than culture-based susceptibility
- Sepsis protocols that tie time-to-appropriate-therapy to measurable outcomes, raising the value of faster organism identification
Market Segmentation
By Type
- Automated phenotypic susceptibility testing instruments
- Kits, reagents and consumables
- Manual susceptibility testing (disc diffusion, broth microdilution)
- Molecular resistance-gene detection assays
- Blood culture and organism identification systems
- Mass spectrometry-based identification
By End User
- Hospital and clinical microbiology laboratories
- Reference and public health laboratories
- Independent and commercial laboratories
- Pharmaceutical and academic research
- Veterinary and food safety laboratories
By Application
- Bloodstream infection and sepsis
- Urinary tract infection
- Respiratory tract infection
- Gastrointestinal infection including Clostridioides difficile
- Surgical site and wound infection
- Public health surveillance
Competitive Landscape
bioMérieux
France
Supplies the VITEK susceptibility and identification range and the BACT/ALERT blood culture range. Group sales were 4,070 million euros in FY2025, up 6.2% organically, with microbiology up 4% organically for the year. Disclosed microbiology sales were 320.4 million euros in the second quarter of 2025 against 324.2 million euros a year earlier, and excluding China the VITEK and BACT/ALERT ranges grew 9% in that quarter on both instruments and reagents while China fell by mid-teens. Annualising the disclosed quarter gives roughly $1.40 billion, which is used in this report only as a plausibility test and not as a share. No AMR-diagnostics share percentage is publicly disclosed.
Becton Dickinson
United States
Supplies the BD Phoenix susceptibility system, BD Kiestra laboratory automation and the BACTEC blood culture range, competing directly with bioMérieux across the same hospital microbiology accounts. Microbiology revenue is reported within a broader Integrated Diagnostic Solutions segment and is not broken out, so neither its size nor its share can be stated.
Thermo Fisher Scientific
United States
Supplies Sensititre broth microdilution and the Oxoid range of discs and media, which remain the reference methods against which automated systems are validated and the practical option for laboratories that cannot fund automation. Revenue sits inside Specialty Diagnostics and is not disclosed at this level of granularity.
Danaher (Cepheid)
United States
GeneXpert cartridges detect specific resistance determinants -- MRSA, carbapenemase genes, rifampicin resistance in tuberculosis -- without culture, which is the only route to a result inside the window in which empiric therapy is chosen. Priced well above culture-based susceptibility per test. Cepheid revenue is reported within Danaher's Diagnostics segment with no resistance-specific line item.
Accelerate Diagnostics
United States
Built entirely around compressing the time from positive blood culture to a susceptibility result, which is the clearest clinical case in the category and the hardest commercial one, because it must displace an installed base that already does the job more slowly and more cheaply. Illustrates why the specialist segment has not changed the market's growth rate. No share figure is public.
Recent Developments
Reported FY2025 group sales of 4,070 million euros, up 6.2% organically, with microbiology up 4% organically for the year after a mid-teens decline in China.
Published its Global Antibiotic Resistance Surveillance Report on 13 October 2025, finding that one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotic treatment in 2023, that resistance rose in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023 at 5 to 15% annually, and that 48% of countries submitted no GLASS data for 2023.
Reported that excluding China, the VITEK and BACT/ALERT ranges grew 9% in the second quarter of 2025 across both instruments and reagents, while total microbiology sales were 320.4 million euros against 324.2 million euros a year earlier.
Regulatory Landscape
Research Methodology
Primary research
- No primary interviews were conducted for this edition. This report is a synthesis of public filings, WHO surveillance publications and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.
Secondary research
- World Health Organization, Global Antibiotic Resistance Surveillance Report, 13 October 2025: one in six laboratory-confirmed bacterial infections resistant in 2023; resistance rose in over 40% of monitored combinations 2018-2023 at 5-15% annually; GLASS participation 25 countries in 2016 to 104 in 2023; 48% of countries did not report for 2023
- bioMérieux, 2025 Financial Results press release: group sales 4,070 million euros FY2025, up 6.2% organic, microbiology up 4% organic
- bioMérieux, H1 2025 Financial Results, and GenomeWeb coverage of Q2 2025: microbiology 320.4 million euros against 324.2 million euros, VITEK and BACT/ALERT up 9% excluding China, China down mid-teens
- Global Market Insights, Antimicrobial Resistance Diagnostics Market, November 2024: $4.4 billion in 2023 to $7.6 billion in 2032; kits and reagents $2.8 billion in 2023; United States at $3.1 billion by 2032 at 6.2%
- Global Industry Analysts, Antimicrobial Resistance Diagnostics, 2024 edition: $4.5 billion in 2024 to $6.1 billion by 2030 at 5.3%
- Allied Market Research, Antimicrobial Susceptibility Testing Market: $3.04 billion in 2020 to $4,736.03 million by 2030 at 5.8%; Research and Markets AST releases of 15 May 2023 and 22 June 2023; Meticulous Research AST release (2024)
- ClinicalTrials.gov API v2, query.term='antimicrobial resistance', retrieved 16 October 2026: 476 registered studies against 607,160 studies in the register
Validation: Market size is taken from published third-party estimates and attributed to each house by name; no methodology behind those estimates was inspected, and they are presented as published estimates rather than as verified measurements. Two plausibility tests were run. First, bioMérieux's disclosed second-quarter 2025 microbiology sales of 320.4 million euros were annualised and converted at $1.09 per euro to roughly $1.40 billion, which is about 31.5% of the $4.45 billion mean of the two independent published base-year figures; because that franchise also includes blood culture and organism identification, the ratio is an upper bound on any AMR-specific share and is used here only to test whether the published market sizes describe a concentrated category. Second, dividing $4.45 billion by the 104 countries reporting to WHO GLASS in 2023 gives $42.8 million per reporting country per year, which makes the skew of this market concrete against a United States figure that one house alone puts at $3.1 billion by 2032. Neither calculation establishes the correct market size, neither is offered as an estimate, and the first rests on a single annualised quarter at a single exchange rate. The 2026 base value is Global Market Insights' published 2023 figure advanced three years at the rate implied by its own published endpoints, not a separately published observation.
Strategic Takeaways
it tells you this is a small, concentrated, slow-growing category, not that the forecasts are well validated
Check any figure you are given against bioMérieux's disclosed microbiology revenue, because one vendor at roughly a third of the market is the constraint every whole-market estimate has to satisfy
resistance is highest where diagnostic capacity is thinnest, and no published forecast assumes that changes
Distinguish susceptibility testing from AMR diagnostics before comparing two reports, because that is the only scope decision that materially moves the number, and it is worth 1.54x
it requires the two-thirds of the market outside the leader to grow at roughly 11% while the leader grew at 4% organically
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Life SciencesVeterinary Diagnostics Market$9.5B · 9.57% CAGR
- Medical ImagingAI in Cancer Diagnostics Market$1.0B · 11.16% CAGR
- Medical DevicesPoint-of-Care Diagnostics Market$35.2B · 7% CAGR
- Life SciencesPharmacogenomics Market$6.8B · 6.6% CAGR
- Life SciencesLiquid Biopsy Market$8.0B · 13.91% CAGR
- Life SciencesSingle-Cell Sequencing Market$2.2B · 12.2% CAGR